181 related articles for article (PubMed ID: 9174208)
1. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae.
Baranova NN; Neyfakh AA
Antimicrob Agents Chemother; 1997 Jun; 41(6):1396-8. PubMed ID: 9174208
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Brenwald NP; Gill MJ; Wise R
Antimicrob Agents Chemother; 1998 Aug; 42(8):2032-5. PubMed ID: 9687402
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the emergence of ciprofloxacin resistance in Streptococcus pneumoniae by the multidrug efflux inhibitor reserpine.
Markham PN
Antimicrob Agents Chemother; 1999 Apr; 43(4):988-9. PubMed ID: 10103220
[TBL] [Abstract][Full Text] [Related]
4. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae.
Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL
Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144
[TBL] [Abstract][Full Text] [Related]
5. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.
Piddock LJ; Johnson MM; Simjee S; Pumbwe L
Antimicrob Agents Chemother; 2002 Mar; 46(3):808-12. PubMed ID: 11850265
[TBL] [Abstract][Full Text] [Related]
6. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.
Zeller V; Janoir C; Kitzis MD; Gutmann L; Moreau NJ
Antimicrob Agents Chemother; 1997 Sep; 41(9):1973-8. PubMed ID: 9303396
[TBL] [Abstract][Full Text] [Related]
7. Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae.
Pestova E; Millichap JJ; Siddiqui F; Noskin GA; Peterson LR
J Antimicrob Chemother; 2002 Mar; 49(3):553-6. PubMed ID: 11864959
[TBL] [Abstract][Full Text] [Related]
8. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.
Brenwald NP; Appelbaum P; Davies T; Gill MJ
Clin Microbiol Infect; 2003 Feb; 9(2):140-3. PubMed ID: 12588335
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae.
Marrer E; Schad K; Satoh AT; Page MG; Johnson MM; Piddock LJ
Antimicrob Agents Chemother; 2006 Feb; 50(2):685-93. PubMed ID: 16436727
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus.
Kaatz GW; Seo SM; O'Brien L; Wahiduzzaman M; Foster TJ
Antimicrob Agents Chemother; 2000 May; 44(5):1404-6. PubMed ID: 10770791
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of patA and patB, which encode ABC transporters, is associated with fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Garvey MI; Baylay AJ; Wong RL; Piddock LJ
Antimicrob Agents Chemother; 2011 Jan; 55(1):190-6. PubMed ID: 20937787
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
[TBL] [Abstract][Full Text] [Related]
13. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
14. The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB.
Garvey MI; Piddock LJ
Antimicrob Agents Chemother; 2008 May; 52(5):1677-85. PubMed ID: 18362193
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.
Piddock LJ; Johnson MM
Antimicrob Agents Chemother; 2002 Mar; 46(3):813-20. PubMed ID: 11850266
[TBL] [Abstract][Full Text] [Related]
16. Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi.
Rafii F; Park M; Wynne R
Chemotherapy; 2005 Aug; 51(5):256-62. PubMed ID: 16088123
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
Harding I; Simpson I
J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
[TBL] [Abstract][Full Text] [Related]
18. The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin.
Brenwald NP; Gill MJ; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):458-60. PubMed ID: 9338508
[No Abstract] [Full Text] [Related]
19. Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones.
Ho PL; Yam WC; Que TL; Tsang DN; Seto WH; Ng TK; Ng WS
J Antimicrob Chemother; 2001 May; 47(5):655-8. PubMed ID: 11328779
[TBL] [Abstract][Full Text] [Related]
20. Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis.
Raherison S; Gonzalez P; Renaudin H; Charron A; Bébéar C; Bébéar CM
Antimicrob Agents Chemother; 2002 Mar; 46(3):672-9. PubMed ID: 11850247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
